You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ferroptosis inhibitor

Showing 1 - 25 of 7,362
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Exposure to Polluted Air Trial in Yangzhou

Active, not recruiting
  • Exposure to Polluted Air
    • Yangzhou, Jiangsu, China
      Wenjing Zhao
    Feb 21, 2023

    PM2.5 Exposure and Ferroptosis in Seizures Patients

    Active, not recruiting
    • Exposure to Polluted Air
      • Wuxi, Jiangsu, China
        Affiliated Hospital of JiangNan University, Department of Pediat
      Mar 5, 2023

      Ferroptosis in COPD COPD With/Without Risk of Cardiovascular

      Recruiting
      • COPD Exacerbation
      • Non-interventional study
      • Santander, Cantabria, Spain
        Hospital Universitario Marqués de Valdecilla
      Oct 25, 2023

      Effects of Lead Exposure on Ferroptosis Pathway

      Recruiting
      • Lead Poisoning
      • Neurotoxicity
      • Lead exposure
      • Yangzhou, Jiangsu, China
        Wenjing Zhao
      Jul 19, 2023

      Oral Mucositis, Lymphoma, Multiple Myeloma Trial in Seoul (MIT-001, normal saline)

      Recruiting
      • Oral Mucositis
      • +3 more
      • Seoul, Korea, Republic of
      • +1 more
      Aug 9, 2022

      Metastatic Colorectal Cancer Trial in Tanta (Sulfasalazine)

      Recruiting
      • Metastatic Colorectal Cancer
      • Tanta, El-Gharbia Governorate, Egypt
        Tanta University Hospital
      Nov 15, 2023

      MDS, Ferroptosis Trial in Pessac (Biological sampling)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Ferroptosis
      • Biological sampling
      • Pessac, France
      • +2 more
      Jun 19, 2023

      IL-9/E-cadherin and Ferroptosis in Intestinal Mucosal Barrier

      Recruiting
      • Sepsis
      • +2 more
      • Standard treatments for sepsis
      • Nanjing, Jiangsu, China
        Nanjing First Hospital
      Jun 5, 2022

      Advanced Solid Tumor, Lung Cancer, Pancreas Cancer Trial in Chengdu (CNSI-Fe(II) 30 mg, CNSI-Fe(II) 60 mg, CNSI-Fe(II) 90 mg)

      Recruiting
      • Advanced Solid Tumor
      • +8 more
      • CNSI-Fe(II) 30 mg
      • +2 more
      • Chengdu, Sichuan, China
        West China Hospital, Sichuan University
      Sep 15, 2023

      Red Blood Cell Disorder, Oxidative Stress, Iron Metabolism Disorders Trial in Poznan (THYROX (Atlantic krill oil)., Placebo)

      Recruiting
      • Red Blood Cell Disorder
      • +2 more
      • THYROX (Atlantic krill oil).
      • Placebo
      • Poznań, Poland
        Poznań University of Physical Education
      Nov 21, 2023

      Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

      Recruiting
      • Peripheral T Cell Lymphoma
      • Linperlisib in combined with Chidamide
      • Beijing, Beijing/China, China
      • +1 more
      Oct 9, 2023

      Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

      Recruiting
      • Cutaneous T-cell Lymphoma
      • Linperlisib in combined with Chidamide
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Sep 8, 2023

      Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

      Not yet recruiting
      • Cervical Cancer
      • Anti-PD-1 antibody balstilimab
      • Amsterdam, Netherlands
        Amsterdam UMC
      Oct 17, 2023

      Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)

      Recruiting
      • Hepatocellular Carcinoma (HCC)
      • Kaohsiung, Taiwan
      • +4 more
      Mar 14, 2023

      HIV Trial in Las Vegas, Austin (VH4004280, Placebo)

      Not yet recruiting
      • HIV Infections
      • Las Vegas, Nevada
      • +1 more
      Aug 21, 2023

      Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

      Not yet recruiting
      • Breast Cancer
      • +4 more
      • (no location specified)
      Aug 31, 2023

      Chronic Kidney Disease Trial (Part A - Lorundrostat QD + Dapaglifozin QD, Part A - Lorundrostat QD, Part B - Lorundrostat QD

      Not yet recruiting
      • Chronic Kidney Disease
      • Part A - Lorundrostat QD + Dapaglifozin QD
      • +2 more
      • (no location specified)
      Nov 27, 2023

      Differentiated Thyroid Cancer Trial in Pavia (Pembrolizumab)

      Not yet recruiting
      • Differentiated Thyroid Cancer
      • Pavia, Lombardia, Italy
        Istituti Clinici Scientifici Maugeri
      May 5, 2023

      Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma Trial in Boston (Zentalis, Gemzar)

      Not yet recruiting
      • Advanced Pancreatic Adenocarcinoma
      • +2 more
      • Boston, Massachusetts
      • +1 more
      Aug 23, 2023

      Blood Vessel Function in Postmenopausal Women With Breast Cancer

      Active, not recruiting
      • Breast Cancer
      • Rochester, Minnesota
        Mayo Clinic
      Jan 17, 2023

      Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

      Not yet recruiting
      • Adenoid Cystic Carcinoma
      • +2 more
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      Mar 14, 2023

      Healthy Trial in Biberach (BI 1810631, Itraconazole)

      Recruiting
      • Healthy
      • Biberach, Germany
        Humanpharmakologisches Zentrum Biberach
      Apr 27, 2023

      Acute Myeloid Leukemia (AML) Trial in Birmingham, San Francisco, New York (ZN-d5 ZN-c3, ZN-c3)

      Recruiting
      • Acute Myeloid Leukemia (AML)
      • Birmingham, Alabama
      • +2 more
      Jan 3, 2023

      Vonoprazan, Helicobacter Pylori Infection, Proton Pump Inhibitor Trial in Hangzhou (Tegoprazan, Esomeprazole)

      Active, not recruiting
      • Vonoprazan
      • +2 more
      • Hangzhou, Zhejiang, China
        Hangzhou first people's Hospital
      Dec 2, 2022

      Atypical Hemolytic Uremic Syndrome (aHUS) Trial in Worldwide (Ravulizumab)

      Active, not recruiting
      Has Results
      • Atypical Hemolytic Uremic Syndrome (aHUS)
      • Ravulizumab
      • Aurora, Colorado
      • +19 more
      Nov 16, 2022